



Final Appraisal Recommendation

Advice No: 2915 – October 2015

Midodrine (Bramox[®]) 2.5 mg and 5 mg tablets

Submission by Brancaster Pharma Ltd

Recommendation of AWMSG

Midodrine hydrochloride (Bramox[®]) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.

Additional note(s):

- The initiation and dose titration of midodrine hydrochloride (Bramox[®]) should be restricted to specialist prescribing.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2650), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Brancaster Pharma Ltd
Date of first issue	October 2015
Last reviewed	March 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2915:
Midodrine hydrochloride (Bramox[®]) 2.5 mg and 5 mg tablets. October 2015.